Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

News Conference News TCT 2020

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

L.A. McKeown

October 22, 2020

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

News Conference News TCT 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

Todd Neale

November 01, 2017

News Industry News TCT 2016

Study Finds No Long-Term Clinical Benefit to Routine Follow-Up Coronary Angiography After PCI

November 01, 2016

News Conference News TCT 2016

Interventionalists Push Transradial PCI in Wider Range of Settings, Including ACS, CTOs, and Calcified Lesions

Michael O'Riordan

October 31, 2016

Presentation TCT 2014

Clinical Outcomes of Patients With High Risk Acute Coronary Syndrome Treated With a New Generation Drug-Eluting Stent, Ultimaster compared with Xience ? Results from CENTURY II___

Presenter: Kazushige Kadota

September 16, 2014

Presentation TCT 2014

Acute Coronary Syndromes (Including STEMI)

Presenter: Azeem Latib, Ron Waksman, Ronald Caputo, Thomas A. Ischinger, Bruno Scheller

September 13, 2014

Presentation TCT 2013

Acute Coronary Syndromes Including STEMI: Is There a Need and a Role for Drug-Coated Balloons?

Presenter: Pieter Stella

October 31, 2013

Presentation TCT 2013

TCT-18. Clinical and Procedural Predictors and Consequences of Stent Thrombosis Following Drug-eluting Stents for Acute Coronary Syndromes: Results From the ADAPT-DES Study

Presenter: Ankit Garg

October 29, 2013

News Conference News TCT 2012

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

November 02, 2012

Presentation TCT 2012

Outcomes After Revascularization with Everolimus- and Sirolimus Eluting Stents In Patients with Acute Coronary Syndromes. A Substudy of the SORT OUT IV Trial.

Presenter: Lisbeth Antonsen, Per Thayssen, Henrik Steen Hansen, Michael Maeng, Hans-Henrik Tilsted, Evald Hoej Christiansen, Knud Noerregaard Hansen, Hans Erik Boetker, Jan Ravkilde, Lars Krusell, Morten Madsen, Henrik Toft Soerensen, Leif Thuesen, Jens Flensted Lassen, Lisette Okkels Jensen

January 03, 2012

News Conference News

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

L.A. McKeown

November 28, 2011

Advertisement

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

Study Finds No Long-Term Clinical Benefit to Routine Follow-Up Coronary Angiography After PCI

Interventionalists Push Transradial PCI in Wider Range of Settings, Including ACS, CTOs, and Calcified Lesions

Clinical Outcomes of Patients With High Risk Acute Coronary Syndrome Treated With a New Generation Drug-Eluting Stent, Ultimaster compared with Xience ? Results from CENTURY II___

Acute Coronary Syndromes (Including STEMI)

Acute Coronary Syndromes Including STEMI: Is There a Need and a Role for Drug-Coated Balloons?

TCT-18. Clinical and Procedural Predictors and Consequences of Stent Thrombosis Following Drug-eluting Stents for Acute Coronary Syndromes: Results From the ADAPT-DES Study

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

Outcomes After Revascularization with Everolimus- and Sirolimus Eluting Stents In Patients with Acute Coronary Syndromes. A Substudy of the SORT OUT IV Trial.

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content